Drug Trial Radar · NCT05704543
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Last checked: Nov 20, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
132
Actual
Start
Mar 1, 2023
Primary completion
Nov 1, 2023
Study completion Nov 1, 2023
Sponsor
- Lead sponsor
- Indivior Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Extended-release buprenorphine (SUBLOCADE®) injection is currently approved for subcutaneous administration in the abdomen for treatment of opioid use disorder (OUD). Having alternative injection sites is desirable to provide additional flexibility to patients, particularly for those who may prefer less visible or more convenient injection locations. The primary objective of this study is to assess the relative bioavailability of extended-release buprenorphine when administered at alternative injection locations (test treatments), in comparison to the abdomen (reference treatment).
Conditions
- Opioid Use Disorder
Interventions
Buprenorphine Extended-Release InjectionDrug
Administered as a subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-time Curve From Study Day 1 to Day 29 (AUC0-28days) of BuprenorphineTime frame: Day 1 at predose and at 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 hours post-dose and on Days 4, 6, 8, 11, 15, 18, 22, 25, and 29
- Maximum Observed Plasma Concentration (Cmax) of BuprenorphineTime frame: Day 1 at predose and at 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 hours post-dose and on Days 4, 6, 8, 11, 15, 18, 22, 25, and 29
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Artemis Institute for Clinical Research
San Diego, California
Research Centers of America
Hollywood, Florida
Miami Lakes Medical Research
Miami Lakes, Florida
Rivus Wellness and Research Institute
Oklahoma City, Oklahoma
InSite Clinical Research, LLC
DeSoto, Texas
Pillar Clinical Research, LLC
Richardson, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.